SwitzerlandDescription
Products
19 productsBrand rhesonativ. Hyperimmune immunoglobulin in the published immunotherapy portfolio; presentations not published.
Tech pack available
Finished product (FDF)
Verified on 2026-10-17
Brand Nuwiq. Recombinant product made in a human cell line, not plasma-derived; haemophilia A.
Tech pack available
Finished product (FDF)
Verified on 2026-10-17
Brand albunorm 20%. Restoration and maintenance of circulating blood volume; 50 and 100 mL packs.
Tech pack available
Finished product (FDF)
Verified on 2026-10-17
Brand albunorm 5%. Restoration and maintenance of circulating blood volume; 250 mL pack.
Tech pack available
Finished product (FDF)
Verified on 2026-10-17
Industrial collaboration line for research and further manufacturing use; presentations not published.
Tech pack available
API (active ingredient)
Verified on 2026-10-17
Brand atenativ. Congenital and acquired antithrombin III deficiency; 500 and 1000 IU vials.
Tech pack available
Finished product (FDF)
Verified on 2026-10-17
Brand octanine F. Prophylaxis and treatment of bleeding in haemophilia B; 500 and 1000 IU vials.
Tech pack available
Finished product (FDF)
Verified on 2026-10-17
Brand octanate. Haemophilia A and acquired factor VIII deficiency; 250, 500 and 1000 IU vials.
Tech pack available
Finished product (FDF)
Verified on 2026-10-17
Brand fibryga. Congenital hypo- or afibrinogenaemia and acquired hypofibrinogenaemia; 1 g vial.
Tech pack available
Finished product (FDF)
Verified on 2026-10-17
Industrial collaboration line for research and further manufacturing use; presentations not published.
Tech pack available
API (active ingredient)
Verified on 2026-10-17
Brand octaplas LG. Complex haemostasis disorders; 200 mL bag with 45-70 mg plasma proteins per mL.
Tech pack available
Finished product (FDF)
Verified on 2026-10-17
Brands octaplex and Balfaxar. Acquired or congenital prothrombin complex factor deficiency; 500 and 1000 IU vials.
Tech pack available
Finished product (FDF)
Verified on 2026-10-17
Industrial collaboration line: pharmaceutical grade albumin for research and further manufacturing use; stated USP/EP/ChP and GMP compliance.
Tech pack available
API (active ingredient)
Verified on 2026-10-17
Brands octagam 10% and panzyga. Primary and secondary immunodeficiency and immunomodulation; 2 g to 30 g packs.
Tech pack available
Finished product (FDF)
Verified on 2026-10-17
Brand octagam 5%. Replacement therapy in immunodeficiency and immunomodulation; 2.5 g, 5 g and 10 g packs.
Tech pack available
Finished product (FDF)
Verified on 2026-10-17
Brands cutaquig and gammanorm. Subcutaneous replacement therapy in primary and secondary immunodeficiency.
Tech pack available
Finished product (FDF)
Verified on 2026-10-17
Industrial collaboration line, 5%, 10% and 16.5% concentrations in several vial sizes.
Tech pack available
API (active ingredient)
Verified on 2026-10-17
Industrial collaboration line for research and further manufacturing use; presentations not published.
Tech pack available
API (active ingredient)
Verified on 2026-10-17
Brand wilate. Von Willebrand disease and haemophilia A; 500 and 1000 IU vials.
Tech pack available
Finished product (FDF)
Verified on 2026-10-17
Von Willebrand Factor: see suppliers → · Factor VIII: see suppliers →
Certifications
Contact company
Other locations
Vienna (Austria)
Stockholm (Sweden)
Springe (Germany)
Dessau (Germany)
Lingolsheim (France)